North America Microvillus Inclusion Disease Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA MICROVILLUS INCLUSION DISEASE MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.8 DBMR MARKET POSITION GRID

2.9 MARKET END USER COVERAGE GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER’S FIVE FORCES

4.2 PESTLE ANALYSIS

4.3 PIPELINE ANALYSIS:

4.3.1 INCIDENCE OF MVID BY GENDER

4.3.2 TREATMENT RATE

4.3.3 MORTALITY RATE

4.3.4 DRUG ADHERENCE & THERAPY SWITCH MODEL

4.3.5 PATIENT TREATMENT SUCCESS RATES

4.4 INDUSTRY INSIGHTS:

4.4.1 MICRO AND MACRO ECONOMIC FACTORS

4.4.2 PENETRATION AND GROWTH PROSPECT MAPPING

4.4.3 KEY PRICING STRATEGIES

4.4.4 ANALYSIS AND RECOMMENDATION

4.5 SUPPLY CHAIN RESILIENCE

4.5.1 DIVERSIFICATION OF PHARMACEUTICAL INGREDIENT AND KEY STARTING MATERIAL SUPPLIERS

4.5.2 ESTABLISHMENT OF REGIONAL PHARMACEUTICAL MANUFACTURING AND PRODUCTION HUBS

4.5.3 STRATEGIC STOCKPILING OF CRITICAL APIS, INTERMEDIATES, AND ESSENTIAL MEDICINES

4.5.4 DEVELOPMENT OF ALTERNATIVE PHARMACEUTICAL LOGISTICS AND COLD CHAIN ROUTES

4.5.5 STRATEGIC PARTNERSHIPS WITH CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CDMOS)

4.5.6 ENERGY & MANUFACTURING OPERATIONAL COST RISK

4.5.6.1 RISING ENERGY COSTS IN PHARMACEUTICAL AND MANUFACTURING FACILITIES

4.5.6.2 INCREASED COSTS FOR RAW MATERIALS, SOLVENTS, AND CHEMICAL INTERMEDIATES

4.5.6.3 ADOPTION OF ENERGY-EFFICIENT PHARMACEUTICAL MANUFACTURING TECHNOLOGIES

4.5.7 GEOGRAPHIC FOOTPRINT REASSESSMENT

4.5.7.1 EXPANSION OF PHARMACEUTICAL MANUFACTURING IN POLITICALLY STABLE REGIONS

4.5.7.2 DIVERSIFICATION OF NORTH AMERICA API AND DRUG MANUFACTURING BASES

4.5.8 SCENARIO PLANNING & RISK MANAGEMENT

4.5.8.1 DEVELOPMENT OF PHARMACEUTICAL SUPPLY CHAIN CONTINGENCY PLANS

4.5.9 CASH & FINANCIAL PROTECTION

4.5.9.1 INVESTMENTS IN DOMESTIC API AND DRUG MANUFACTURING INFRASTRUCTURE

4.5.10 DATA PROTECTION

4.5.10.1 PROTECTION OF CLINICAL TRIAL DATA, PATIENT DATA, AND DRUG DEVELOPMENT INFORMATION

4.5.10.2 NEW BUSINESS AND EMERGING REVENUE OPPORTUNITIES & FUTURE OUTLOOK

4.6 PATENT ANALYSIS

4.6.1 DRUG

4.6.1.1 BRAND NAME

4.6.1.2 GENERIC NAME

4.6.2 THERAPEUTIC INDICATION

4.6.3 PHARMACOLOGICAL CLASS OF THE DRUG

4.6.4 DRUG PRIMARY INDICATION

4.6.5 MARKET STATUS

4.6.6 MEDICATION TYPE

4.6.7 DRUG DOSAGE FORM

4.6.8 DOSAGE AVAILABILITY

4.6.9 PACKAGING TYPE

4.6.10 DRUG ROUTE OF ADMINISTRATION

4.6.11 DOSING FREQUENCY

4.6.12 DRUG INSIGHT

4.7 PATENT ANALYSIS

4.7.1 PATENT FILING LANDSCAPE

4.7.2 GEOGRAPHIC DISTRIBUTION OF PATENT FILINGS

4.7.3 KEY PATENT APPLICANTS AND ASSIGNEES

4.7.4 INVENTOR LANDSCAPE AND RESEARCH CONTRIBUTION

4.7.5 IPC CODE ANALYSIS

4.7.6 PUBLICATION TREND ANALYSIS

4.7.7 COMPETITIVE PATENT INTENSITY AND FUTURE OUTLOOK

4.8 PIPELINE ANALYSIS:

4.8.1 CLINICAL TRIALS AND PHASE ANALYSIS

4.8.2 DRUG THERAPY PIPELINE

4.8.3 PHASE III CANDIDATES

4.8.4 PHASE II CANDIDATES

4.8.5 PHASE I CANDIDATES

4.8.6 OTHERS (PRE-CLINICAL AND RESEARCH)

4.9 R&D ANALYSIS

4.9.1 COMPARATIVE ANALYS

4.9.2 DRUG DEVELOPMENTAL LANDSCAPE

4.9.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES

4.9.4 THERAPEUTIC ASSESSMENT

4.9.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS

5 HEALTHCARE TARIFFS IMPACT ANALYSIS

5.1 OVERVIEW

5.2 TARIFF STRUCTURES

5.2.1 NORTH AMERICA VS. REGIONAL TARIFF STRUCTURES

5.2.2 UNITED STATES: MEDICARE/MEDICAID TARIFF POLICIES, CMS PRICING MODELS

5.2.3 EUROPEAN UNION: CROSS-BORDER TARIFF REGULATIONS, REIMBURSEMENT POLICIES

5.2.4 EMERGING MARKETS: CHALLENGES IN TARIFF IMPLEMENTATION

5.3 PHARMACEUTICAL TARIFFS AND TRADE BARRIERS

5.3.1 IMPORT DUTIES ON PRESCRIPTION DRUGS VS. GENERICS

5.3.2 IMPACT ON DRUG AFFORDABILITY AND ACCESS

5.3.3 KEY TRADE AGREEMENTS AFFECTING PHARMACEUTICAL TARIFFS

5.4 IMPACT OF HEALTHCARE TARIFFS ON PROVIDERS AND PATIENTS

5.4.1 COST BURDEN ON HOSPITALS AND HEALTHCARE FACILITIES

5.4.2 EFFECT ON PATIENT AFFORDABILITY AND INSURANCE COVERAGE

5.5 TRADE AGREEMENTS AND HEALTHCARE TARIFFS

5.5.1 IMPACT OF TRADE WARS ON THE HEALTHCARE SUPPLY CHAIN

5.5.2 ROLE OF FREE TRADE AGREEMENTS (FTAS) IN REDUCING TARIFFS

5.6 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY

5.7 IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR

6 REGULATORY FRAMEWORK

6.1 REGULATORY APPROVAL PROCESS

6.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL

6.3 REGULATORY APPROVAL PATHWAYS

6.4 LICENSING AND REGISTRATION

6.5 POST-MARKETING SURVEILLANCE (PMS)

6.6 GOOD MANUFACTURING PRACTICES (GMP) GUIDELINES

7 MARKET OVERVIEW

7.1 DRIVER

7.1.1 ADVANCEMENTS IN GENETIC DIAGNOSTICS AND NEXT-GENERATION SEQUENCING

7.1.2 INCREASING INVESTMENT IN RARE DISEASE AND ORPHAN DRUG RESEARCH

7.1.3 CLINICAL AWARENESS AND IMPROVED NEONATAL SCREENING

7.1.4 GROWING DEMAND FOR ADVANCED SUPPORTIVE CARE AND LONG-TERM PATIENT MANAGEMENT

7.2 RESTRAINTS

7.2.1 EXTREMELY LOW DISEASE PREVALENCE OF MVID

7.2.2 HIGH COST OF TREATMENT (ESPECIALLY TPN AND TRANSPLANTATION)

7.3 OPPORTUNITY

7.3.1 EMERGENCE OF GENE THERAPY TARGETING MYO5B MUTATIONS

7.3.2 ADVANCEMENTS IN ORGANOID-BASED AND STEM CELL THERAPIES

7.3.3 COLLABORATIONS BETWEEN RESEARCH INSTITUTES AND PHARMA COMPANIES

7.4 CHALLENGES

7.4.1 HIGH RISK ASSOCIATED WITH TRANSPLANT PROCEDURES

7.4.2 DIFFICULTIES IN CONDUCTING CLINICAL TRIALS

8 NORTH AMERICA MICROVILLUS INCLUSION DISEASE MARKET, BY DISEASE TYPE / CLINICAL PRESENTATION

8.1 OVERVIEW

8.2 NORTH AMERICA MICROVILLUS INCLUSION DISEASE MARKET, BY DISEASE TYPE / CLINICAL PRESENTATION, 2018-2033 (USD THOUSAND)

8.2.1 EARLY-ONSET (CONGENITAL) MVID

8.2.2 GENETIC SUBTYPES

8.2.3 NON-SYNDROMIC MVID

8.2.4 SYNDROMIC MVID

8.2.5 LATE-ONSET / ATYPICAL MVID

8.3 NORTH AMERICA EARLY-ONSET (CONGENITAL) MVID IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

8.3.1 NORTH AMERICA

8.3.2 EUROPE

8.3.3 ASIA-PACIFIC

8.3.4 MIDDLE EAST AND AFRICA

8.3.5 SOUTH AMERICA

8.4 NORTH AMERICA GENETIC SUBTYPES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

8.4.1 MYO5B MUTATION-ASSOCIATED MVID

8.4.2 STX3 MUTATION-ASSOCIATED MVID

8.4.3 STXBP2 MUTATION-ASSOCIATED MVID

8.4.4 OTHER RARE GENETIC VARIANTS

8.4.5 UNC45A MUTATION-ASSOCIATED MVID

8.5 NORTH AMERICA GENETIC SUBTYPES IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

8.5.1 NORTH AMERICA

8.5.2 EUROPE

8.5.3 ASIA-PACIFIC

8.5.4 MIDDLE EAST AND AFRICA

8.5.5 SOUTH AMERICA

8.6 NORTH AMERICA NON-SYNDROMIC MVID IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

8.6.1 NORTH AMERICA

8.6.2 EUROPE

8.6.3 ASIA-PACIFIC

8.6.4 MIDDLE EAST AND AFRICA

8.6.5 SOUTH AMERICA

8.7 NORTH AMERICA SYNDROMIC MVID IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

8.7.1 NORTH AMERICA

8.7.2 EUROPE

8.7.3 ASIA-PACIFIC

8.7.4 MIDDLE EAST AND AFRICA

8.7.5 SOUTH AMERICA

8.8 NORTH AMERICA LATE-ONSET / ATYPICAL MVID IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

8.8.1 NORTH AMERICA

8.8.2 EUROPE

8.8.3 ASIA-PACIFIC

8.8.4 MIDDLE EAST AND AFRICA

8.8.5 SOUTH AMERICA

9 NORTH AMERICA MICROVILLUS INCLUSION DISEASE MARKET, BY TREATMENT TYPE

9.1 OVERVIEW

9.2 NORTH AMERICA MICROVILLUS INCLUSION DISEASE MARKET, BY TREATMENT TYPE, 2018-2033 (USD THOUSAND)

9.2.1 NUTRITIONAL SUPPORT

9.2.2 SURGICAL & ADVANCED INTERVENTIONS

9.2.3 PHARMACOLOGICAL MANAGEMENT

9.2.4 EMERGING & PIPELINE THERAPIES

9.3 NORTH AMERICA NUTRITIONAL SUPPORT IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

9.3.1 NORTH AMERICA

9.3.2 EUROPE

9.3.3 ASIA-PACIFIC

9.3.4 MIDDLE EAST AND AFRICA

9.3.5 SOUTH AMERICA

9.4 NORTH AMERICA NUTRITIONAL SUPPORT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.4.1 SPECIALIZED PEDIATRIC NUTRITIONAL FORMULATIONS

9.4.2 ENTERAL NUTRITION (MINIMAL / ADJUNCT)

9.5 NORTH AMERICA TOTAL PARENTERAL NUTRITION (TPN) IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.5.1 OTHERS (AMINO ACIDS, LIPIDS, GLUCOSE, ELECTROLYTES, VITAMINS, TRACE ELEMENTS)

9.5.2 GLUTAMINE

9.6 NORTH AMERICA SURGICAL & ADVANCED INTERVENTIONS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.6.1 INTESTINAL TRANSPLANTATION

9.6.2 COMBINED LIVER-INTESTINAL TRANSPLANT

9.6.3 OTHERS

9.7 NORTH AMERICA SURGICAL & ADVANCED INTERVENTIONS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

9.7.1 NORTH AMERICA

9.7.2 EUROPE

9.7.3 ASIA-PACIFIC

9.7.4 MIDDLE EAST AND AFRICA

9.7.5 SOUTH AMERICA

9.8 NORTH AMERICA PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.8.1 ELECTROLYTE REPLACEMENT THERAPIES

9.8.2 ANTIBIOTICS (INFECTION CONTROL)

9.8.3 HEPATOPROTECTIVE AGENTS (TPN-INDUCED LIVER DISEASE)

9.8.4 ANTI-DIARRHEAL AGENTS

9.8.5 ANTI-SECRETORY AGENTS

9.8.6 OTHERS

9.9 NORTH AMERICA PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

9.9.1 NORTH AMERICA

9.9.2 EUROPE

9.9.3 ASIA-PACIFIC

9.9.4 MIDDLE EAST AND AFRICA

9.9.5 SOUTH AMERICA

9.1 NORTH AMERICA ANTI-SECRETORY AGENTS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.10.1 OCTREOTIDE

9.10.2 SOMATOSTATIN

9.10.3 LOPERAMIDE

9.10.4 CHLORPROMAZINE

9.10.5 OTHERS

9.11 NORTH AMERICA PHARMACOLOGICAL MANAGEMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY DRUG, 2018-2033 (USD THOUSAND)

9.11.1 GENERICS

9.11.2 BRANDED

9.12 NORTH AMERICA BRANDED IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.12.1 SANDOSTATIN

9.12.2 IMODIUM

9.12.3 MYCAPSSA

9.12.4 BYNFEZIA

9.12.5 DIAMODE

9.12.6 OTHERS

9.13 NORTH AMERICA EMERGING & PIPELINE THERAPIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

9.13.1 GENE THERAPY (MYO5B CORRECTION)

9.13.2 STEM CELL THERAPY

9.13.3 ORGANOID-BASED THERAPIES

9.13.4 PRECISION MEDICINE / TARGETED MOLECULAR THERAPY

9.14 NORTH AMERICA EMERGING & PIPELINE THERAPIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

9.14.1 NORTH AMERICA

9.14.2 EUROPE

9.14.3 ASIA-PACIFIC

9.14.4 MIDDLE EAST AND AFRICA

9.14.5 SOUTH AMERICA

10 NORTH AMERICA MICROVILLUS INCLUSION DISEASE MARKET, BY ROUTE OF ADMINISTRATION

10.1 OVERVIEW

10.2 NORTH AMERICA MICROVILLUS INCLUSION DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)

10.2.1 INTRAVENOUS (IV)

10.2.2 ORAL

10.2.3 SUBCUTANEOUS

10.2.4 ENTERAL

10.2.5 OTHERS

10.3 NORTH AMERICA INTRAVENOUS (IV) IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

10.3.1 NORTH AMERICA

10.3.2 EUROPE

10.3.3 ASIA-PACIFIC

10.3.4 MIDDLE EAST AND AFRICA

10.3.5 SOUTH AMERICA

10.4 NORTH AMERICA ORAL IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

10.4.1 NORTH AMERICA

10.4.2 EUROPE

10.4.3 ASIA-PACIFIC

10.4.4 MIDDLE EAST AND AFRICA

10.4.5 SOUTH AMERICA

10.5 NORTH AMERICA SUBCUTANEOUS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

10.5.1 NORTH AMERICA

10.5.2 EUROPE

10.5.3 ASIA-PACIFIC

10.5.4 MIDDLE EAST AND AFRICA

10.5.5 SOUTH AMERICA

10.6 NORTH AMERICA ENTERAL IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

10.6.1 NORTH AMERICA

10.6.2 EUROPE

10.6.3 ASIA-PACIFIC

10.6.4 MIDDLE EAST AND AFRICA

10.6.5 SOUTH AMERICA

10.7 NORTH AMERICA OTHERS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

10.7.1 NORTH AMERICA

10.7.2 EUROPE

10.7.3 ASIA-PACIFIC

10.7.4 MIDDLE EAST AND AFRICA

10.7.5 SOUTH AMERICA

11 NORTH AMERICA MICROVILLUS INCLUSION DISEASE MARKET, BY DIAGNOSIS TYPE

11.1 OVERVIEW

11.2 NORTH AMERICA MICROVILLUS INCLUSION DISEASE MARKET, BY DIAGNOSIS TYPE, 2018-2033 (USD THOUSAND)

11.2.1 GENETIC TESTING

11.2.2 DEFINITIVE DIAGNOSTICS

11.2.3 LABORATORY TESTING

11.2.4 IMAGING & SUPPORT DIAGNOSTICS

11.3 NORTH AMERICA GENETIC TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

11.3.1 NORTH AMERICA

11.3.2 EUROPE

11.3.3 ASIA-PACIFIC

11.3.4 MIDDLE EAST AND AFRICA

11.3.5 SOUTH AMERICA

11.4 NORTH AMERICA GENETIC TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

11.4.1 POSTNATAL GENETIC TESTING

11.4.2 PRENATAL GENETIC SCREENING

11.4.3 CARRIER SCREENING

11.4.4 OTHERS

11.5 NORTH AMERICA DEFINITIVE DIAGNOSTICS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

11.5.1 SMALL INTESTINAL BIOPSY

11.5.2 ELECTRON MICROSCOPY

11.5.3 OTHERS

11.6 NORTH AMERICA DEFINITIVE DIAGNOSTICS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

11.6.1 NORTH AMERICA

11.6.2 EUROPE

11.6.3 ASIA-PACIFIC

11.6.4 MIDDLE EAST AND AFRICA

11.6.5 SOUTH AMERICA

11.7 NORTH AMERICA LABORATORY TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

11.7.1 ELECTROLYTE PANELS

11.7.2 STOOL ANALYSIS

11.7.3 NUTRITIONAL DEFICIENCY TESTING

11.7.4 OTHERS

11.8 NORTH AMERICA LABORATORY TESTING IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

11.8.1 NORTH AMERICA

11.8.2 EUROPE

11.8.3 ASIA-PACIFIC

11.8.4 MIDDLE EAST AND AFRICA

11.8.5 SOUTH AMERICA

12 NORTH AMERICA MICROVILLUS INCLUSION DISEASE MARKET, BY END USER

12.1 OVERVIEW

12.2 NORTH AMERICA MICROVILLUS INCLUSION DISEASE MARKET, BY END USER, 2018-2033 (USD THOUSAND)

12.2.1 HOSPITALS

12.2.2 PEDIATRIC SPECIALTY CLINICS

12.2.3 HOME HEALTHCARE SETTINGS (TPN ADMINISTRATION)

12.2.4 TRANSPLANT CENTERS

12.2.5 RESEARCH INSTITUTES & ACADEMIC CENTERS

12.2.6 OTHERS

12.3 NORTH AMERICA HOSPITALS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

12.3.1 NORTH AMERICA

12.3.2 EUROPE

12.3.3 ASIA-PACIFIC

12.3.4 MIDDLE EAST AND AFRICA

12.3.5 SOUTH AMERICA

12.4 NORTH AMERICA HOSPITALS IN MICROVILLUS INCLUSION DISEASE MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

12.4.1 PUBLIC HOSPITALS

12.4.2 PRIVATE HOSPITALS

12.5 NORTH AMERICA PEDIATRIC SPECIALTY CLINICS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

12.5.1 NORTH AMERICA

12.5.2 EUROPE

12.5.3 ASIA-PACIFIC

12.5.4 MIDDLE EAST AND AFRICA

12.5.5 SOUTH AMERICA

12.6 NORTH AMERICA HOME HEALTHCARE SETTINGS (TPN ADMINISTRATION) IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

12.6.1 NORTH AMERICA

12.6.2 EUROPE

12.6.3 ASIA-PACIFIC

12.6.4 MIDDLE EAST AND AFRICA

12.6.5 SOUTH AMERICA

12.7 NORTH AMERICA TRANSPLANT CENTERS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

12.7.1 NORTH AMERICA

12.7.2 EUROPE

12.7.3 ASIA-PACIFIC

12.7.4 MIDDLE EAST AND AFRICA

12.7.5 SOUTH AMERICA

12.8 NORTH AMERICA RESEARCH INSTITUTES & ACADEMIC CENTERS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

12.8.1 NORTH AMERICA

12.8.2 EUROPE

12.8.3 ASIA-PACIFIC

12.8.4 MIDDLE EAST AND AFRICA

12.8.5 SOUTH AMERICA

12.9 NORTH AMERICA OTHERS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

12.9.1 NORTH AMERICA

12.9.2 EUROPE

12.9.3 ASIA-PACIFIC

12.9.4 MIDDLE EAST AND AFRICA

12.9.5 SOUTH AMERICA

13 NORTH AMERICA MICROVILLUS INCLUSION DISEASE MARKET, BY PATIENT DEMOGRAPHICS

13.1 OVERVIEW

13.2 NORTH AMERICA MICROVILLUS INCLUSION DISEASE MARKET, BY PATIENT DEMOGRAPHICS, 2018-2033 (USD THOUSAND)

13.2.1 NEONATES

13.2.2 INFANTS

13.2.3 PEDIATRIC (LONG-TERM SURVIVORS)

13.3 NORTH AMERICA NEONATES IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

13.3.1 NORTH AMERICA

13.3.2 EUROPE

13.3.3 ASIA-PACIFIC

13.3.4 MIDDLE EAST AND AFRICA

13.3.5 SOUTH AMERICA

13.4 NORTH AMERICA INFANTS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

13.4.1 NORTH AMERICA

13.4.2 EUROPE

13.4.3 ASIA-PACIFIC

13.4.4 MIDDLE EAST AND AFRICA

13.4.5 SOUTH AMERICA

13.5 NORTH AMERICA PEDIATRIC (LONG-TERM SURVIVORS) IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

13.5.1 NORTH AMERICA

13.5.2 EUROPE

13.5.3 ASIA-PACIFIC

13.5.4 MIDDLE EAST AND AFRICA

13.5.5 SOUTH AMERICA

14 NORTH AMERICA MICROVILLUS INCLUSION DISEASE MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 NORTH AMERICA MICROVILLUS INCLUSION DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

14.2.1 HOSPITAL PHARMACIES

14.2.2 SPECIALTY PHARMACIES

14.2.3 DIRECT PROCUREMENT

14.2.4 ONLINE PHARMACIES

14.2.5 OTHERS

14.3 NORTH AMERICA HOSPITAL PHARMACIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

14.3.1 NORTH AMERICA

14.3.2 EUROPE

14.3.3 ASIA-PACIFIC

14.3.4 MIDDLE EAST AND AFRICA

14.3.5 SOUTH AMERICA

14.4 NORTH AMERICA SPECIALTY PHARMACIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

14.4.1 NORTH AMERICA

14.4.2 EUROPE

14.4.3 ASIA-PACIFIC

14.4.4 MIDDLE EAST AND AFRICA

14.4.5 SOUTH AMERICA

14.5 NORTH AMERICA DIRECT PROCUREMENT IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

14.5.1 NORTH AMERICA

14.5.2 EUROPE

14.5.3 ASIA-PACIFIC

14.5.4 MIDDLE EAST AND AFRICA

14.5.5 SOUTH AMERICA

14.6 NORTH AMERICA ONLINE PHARMACIES IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

14.6.1 NORTH AMERICA

14.6.2 EUROPE

14.6.3 ASIA-PACIFIC

14.6.4 MIDDLE EAST AND AFRICA

14.6.5 SOUTH AMERICA

14.7 NORTH AMERICA OTHERS IN MICROVILLUS INCLUSION DISEASE MARKET, BY REGION, 2018-2033 (USD THOUSAND)

14.7.1 NORTH AMERICA

14.7.2 EUROPE

14.7.3 ASIA-PACIFIC

14.7.4 MIDDLE EAST AND AFRICA

14.7.5 SOUTH AMERICA

15 NORTH AMERICA MICROVILLUS INCLUSION DISEASE MARKET, BY REGION

15.1 NORTH AMERICA

15.1.1 U.S.

15.1.2 CANADA

15.1.3 MEXICO

16 NORTH AMERICA MICROVILLUS INCLUSION DISEASE MARKET: COMPANY LANDSCAPE

16.1 MANUFACTURER COMPANY SHARE ANALYSIS: GLOBAL

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 BAXTER INTERNATIONAL INC.

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 COMPANY SHARE ANALYSIS

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENT

18.2 FRESENIUS SE & CO. KGAA

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENT

18.3 B BRAUN SE

18.3.1 COMPANY SNAPSHOT

18.3.2 COMPANY SHARE ANALYSIS

18.3.3 PRODUCT PORTFOLIO

18.3.4 RECENT DEVELOPMENT

18.4 NESTLÉ HEALTH SCIENCE

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 COMPANY SHARE ANALYSIS

18.4.4 PRODUCT PORTFOLIO

18.4.5 RECENT DEVELOPMENT

18.5 NUTRICIA (DANONE GROUP)

18.5.1 COMPANY SNAPSHOT

18.5.2 REVENUE ANALYSIS

18.5.3 COMPANY SHARE ANALYSIS

18.5.4 PRODUCT PORTFOLIO

18.5.5 RECENT DEVELOPMENT

18.6 ABBOTT LABORATORIES

18.6.1 COMPANY SNAPSHOT

18.6.2 REVENUE ANALYSIS

18.6.3 PRODUCT PORTFOLIO

18.6.4 RECENT DEVELOPMENT

18.7 ACULIFE HEALTHCARE PVT. LTD.

18.7.1 COMPANY SNAPSHOT

18.7.2 PRODUCT PORTFOLIO

18.7.3 RECENT DEVELOPMENT

18.8 AJINOMOTO CAMBROOKE, INC

18.8.1 COMPANY SNAPSHOT

18.8.2 PRODUCT PORTFOLIO

18.8.3 RECENT DEVELOPMENT

18.9 CHIESI FARMACEUTICI S.P.A.

18.9.1 COMPANY SNAPSHOT

18.9.2 PRODUCT PORTFOLIO

18.9.3 RECENT DEVELOPMENT

18.1 EMYRIS BIOLIFESCIENCES

18.10.1 COMPANY SNAPSHOT

18.10.2 PRODUCT PORTFOLIO

18.10.3 RECENT DEVELOPMENT

18.11 FUNCTIONAL FORMULARIES.

18.11.1 COMPANY SNAPSHOT

18.11.2 PRODUCT PORTFOLIO

18.11.3 RECENT DEVELOPMENT

18.12 GEDEON RICHTER PLC.

18.12.1 COMPANY SNAPSHOT

18.12.2 REVENUE ANALYSIS

18.12.3 PRODUCT PORTFOLIO

18.12.4 RECENT DEVELOPMENTS

18.13 HEXAGON NUTRITION LTD.

18.13.1 COMPANY SNAPSHOT

18.13.2 PRODUCT PORTFOLIO

18.13.3 RECENT DEVELOPMENT

18.14 IPSEN S.A.

18.14.1 COMPANY SNAPSHOT

18.14.2 REVENUE ANALYSIS

18.14.3 PRODUCT PORTFOLIO

18.14.4 RECENT DEVELOPMENT

18.15 NAPO PHARMACEUTICALS (PART OF JAGUAR HEALTH, INC)

18.15.1 COMPANY SNAPSHOT

18.15.2 REVENUE ANALYSIS

18.15.3 PRODUCT PORTFOLIO

18.15.4 RECENT DEVELOPMENT

18.16 KATE FARMS

18.16.1 COMPANY SNAPSHOT

18.16.2 PRODUCT PORTFOLIO

18.16.3 RECENT DEVELOPMENT

18.17 KENVUE

18.17.1 COMPANY SNAPSHOT

18.17.2 REVENUE ANALYSIS

18.17.3 PRODUCT PORTFOLIO

18.17.4 RECENT DEVELOPMENT

18.18 LABORATOIRE AGUETTANT

18.18.1 COMPANY SNAPSHOT

18.18.2 PRODUCT PORTFOLIO

18.18.3 RECENT DEVELOPMENT

18.19 LUOXIN PHARMACEUTICALS GROUP STOCK COLTD

18.19.1 COMPANY SNAPSHOT

18.19.2 REVENUE ANALYSIS

18.19.3 PRODUCT PORTFOLIO

18.19.4 RECENT DEVELOPMENT

18.2 NOVARTIS AG

18.20.1 COMPANY SNAPSHOT

18.20.2 REVENUE ANALYSIS

18.20.3 PRODUCT PORTFOLIO

18.20.4 RECENT DEVELOPMENT

18.21 NOVUS LIFESCIENCES PVT. LTD.

18.21.1 COMPANY SNAPSHOT

18.21.2 PRODUCT PORTFOLIO

18.21.3 RECENT DEVELOPMENT

18.22 NUTRISENS MEDICAL ITALIA

18.22.1 COMPANY SNAPSHOT

18.22.2 PRODUCT PORTFOLIO

18.22.3 RECENT DEVELOPMENT

18.23 OSCAR REMEDIES PRIVATE LIMITED

18.23.1 COMPANY SNAPSHOT

18.23.2 PRODUCT PORTFOLIO

18.23.3 RECENT DEVELOPMENT

18.24 OTSUKA PHARMACEUTICAL INDIA PRIVATE LIMITED

18.24.1 COMPANY SNAPSHOT

18.24.2 PRODUCT PORTFOLIO

18.24.3 RECENT DEVELOPMENT

18.25 PENTAGON LABS LTD

18.25.1 COMPANY SNAPSHOT

18.25.2 PRODUCT PORTFOLIO

18.25.3 RECENT DEVELOPMENT

18.26 PFIZER INC.

18.26.1 COMPANY SNAPSHOT

18.26.2 REVENUE ANALYSIS

18.26.3 PRODUCT PORTFOLIO

18.26.4 RECENT DEVELOPMENT

18.27 PHEBRA PTY LTD

18.27.1 COMPANY SNAPSHOT

18.27.2 PRODUCT PORTFOLIO

18.27.3 RECENT DEVELOPMENT

18.28 PRISTINE ORGANICS PVT LTD.

18.28.1 COMPANY SNAPSHOT

18.28.2 PRODUCT PORTFOLIO

18.28.3 RECENT DEVELOPMENT

18.29 SICHUAN KELUN PHARMACEUTICAL CO., LTD.

18.29.1 COMPANY SNAPSHOT

18.29.2 REVENUE ANALYSIS

18.29.3 PRODUCT PORTFOLIO

18.29.4 RECENT DEVELOPMENT

18.3 SUN PHARMACEUTICAL INDUSTRIES LTD.

18.30.1 COMPANY SNAPSHOT

18.30.2 REVENUE ANALYSIS

18.30.3 PRODUCT PORTFOLIO

18.30.4 RECENT DEVELOPMENTS

18.31 TEVA PHARMACEUTICAL INDUSTRIES LTD.

18.31.1 COMPANY SNAPSHOT

18.31.2 REVENUE ANALYSIS

18.31.3 PRODUCT PORTFOLIO

18.31.4 RECENT DEVELOPMENT

18.32 USV PRIVATE LIMITED

18.32.1 COMPANY SNAPSHOT

18.32.2 PRODUCT PORTFOLIO

18.32.3 RECENT DEVELOPMENT

19 QUESTIONNAIRE

20 RELATED REPORTS